Ra Capital Management, LLC
revealed that they own 9.9% of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in a Form 13D/A disclosure that was filed with the SEC on Wednesday, December 20th. The investor owns 5,074,013 shares of the stock valued at about $40,490,624. The reporting parties listed on the disclosure included RA Capital Management, LLC, Peter Kolchinsky and RA Capital Healthcare Fund, LP. The filing is available through Edgar at this link.
In related news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 29.41% of the stock is owned by corporate insiders.
Several analysts have issued reports on the company. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price (up from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $6.81.
Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) traded up $0.63 during trading hours on Wednesday, reaching $7.98. The company’s stock had a trading volume of 290,128 shares, compared to its average volume of 180,780. Dicerna Pharmaceuticals Inc has a 12 month low of $2.42 and a 12 month high of $10.24.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). The company had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The firm’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.68) EPS. equities research analysts anticipate that Dicerna Pharmaceuticals Inc will post -3.04 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/20/ra-capital-management-llc-has-9-9-stake-in-dicerna-pharmaceuticals-inc-drna.html.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
What are top analysts saying about Dicerna Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dicerna Pharmaceuticals and related companies.